Drug intelligence / Profile preview

dexamethasone + pranoprofen + sodium hyaluronate + tobramycin

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Ophthalmic

Overview

A combination eye drop formulation containing dexamethasone (a corticosteroid), pranoprofen (a non-steroidal anti-inflammatory drug), sodium hyaluronate (a lubricant), and tobramycin (an aminoglycoside antibiotic). This combination is primarily used to treat dry eye disease following cataract surgery (phacoemulsification). The components work synergistically to reduce inflammation, prevent infection, and provide lubrication to the eye surface.

Targets

16S rRNA (16S ribosomal RNA)23S rRNA (23S ribosomal RNA)GR (Glucocorticoid receptor)COX

Beyond the preview

Go deeper on dexamethasone + pranoprofen + sodium hyaluronate + tobramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + pranoprofen + sodium hyaluronate + tobramycin.

Explore the full profile